Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket TrialPARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it has selected a leading contract research organization (CRO) for SOTERIA, a phase 2, open-label, single-arm trial designed to evaluate the safety, tolerability, and clinical activity of Polaryx’s lead candidate, PLX-200, across four different LSDs.
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil)
Polaryx Therapeutics Welcomes New Members of the Board of DirectorsPARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx’s Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member of the Board effective on the same date.
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial LaunchOral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200
